{
    "clinical_study": {
        "@rank": "151356", 
        "arm_group": [
            {
                "arm_group_label": "Sequence 1: Placebo + TAK-063 Dose 1 + TAK-063 Dose 2", 
                "arm_group_type": "Experimental", 
                "description": "Period 1, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 Dose 1 and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 Dose 2 and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.\nPeriod 1 & 2 are followed by 7 day washout period."
            }, 
            {
                "arm_group_label": "Sequence 2: TAK-063 Dose 1 + TAK-063 Dose 2 + Placebo", 
                "arm_group_type": "Experimental", 
                "description": "Period 1, Day 1: TAK-063 Dose 1 and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 Dose 2 and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1:  TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.\nPeriod 1 & 2 are followed by 7 day washout period."
            }, 
            {
                "arm_group_label": "Sequence 3: TAK-063 Dose 2 + Placebo + TAK-063 Dose 1", 
                "arm_group_type": "Experimental", 
                "description": "Period 1, Day 1: TAK-063 Dose 2 and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 Dose 1 and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.\nPeriod 1 & 2 are followed by 7 day washout period."
            }, 
            {
                "arm_group_label": "Sequence 4: Placebo + TAK-063 Dose 1 + TAK-063 Dose 3", 
                "arm_group_type": "Experimental", 
                "description": "Period 1, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 Dose 1 and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 Dose 3 and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.\nPeriod 1 & 2 are followed by 7 day washout period."
            }, 
            {
                "arm_group_label": "Sequence 5: TAK-063 Dose 1 + TAK-063 Dose 3 + Placebo", 
                "arm_group_type": "Experimental", 
                "description": "Period 1, Day 1: TAK-063 Dose 1 and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 Dose 3 and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1:  TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.\nPeriod 1 & 2 are followed by 7 day washout period"
            }, 
            {
                "arm_group_label": "Sequence 6: TAK-063 Dose 3 + Placebo + TAK-063 Dose 1", 
                "arm_group_type": "Experimental", 
                "description": "Period 1, Day 1: TAK-063 Dose 3 and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 Dose 1 and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.\nPeriod 1 & 2 are followed by 7 day washout period."
            }, 
            {
                "arm_group_label": "Sequence 7: Placebo + TAK-063 Dose 2 + TAK-063 Dose 3", 
                "arm_group_type": "Experimental", 
                "description": "Period 1, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight:\nPeriod 2, Day 1: TAK-063 Dose 2 and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 Dose 3 and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.\nPeriod 1 & 2 are followed by 7 day washout period."
            }, 
            {
                "arm_group_label": "Sequence 8: TAK-063 Dose 2 + TAK-063 Dose 3 + Placebo", 
                "arm_group_type": "Experimental", 
                "description": "Period 1, Day 1: TAK-063 Dose 2 and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 Dose 3 and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.\nPeriod 1 & 2 are followed by 7 day washout period."
            }, 
            {
                "arm_group_label": "Sequence 9: TAK-063 Dose 3 + Placebo + TAK-063 Dose 2", 
                "arm_group_type": "Experimental", 
                "description": "Period 1, Day 1: TAK-063 Dose 3 and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 Dose 2 and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight. Period 1 & 2 are followed by 7 day washout period."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether ketamine-induced brain activity changes\n      are modulated by TAK-063 administration using neuroimaging battery tests."
        }, 
        "brief_title": "Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Ketamine-Induced Brain Activity Changes", 
            "Psychotic-like Symptoms"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Mental Disorders", 
                "Psychotic Disorders"
            ]
        }, 
        "detailed_description": {
            "textblock": "The drug being tested in this study is called TAK-063. This study will look at brain\n      activity changes and treatment of psychotic-like symptoms induced by Ketamine, in people who\n      take TAK-063.\n\n      The study will enroll approximately 27 patients. Participants will be randomly assigned  to\n      one of treatment sequences\u2014which will remain undisclosed to the patient during the study\n      (unless there is an urgent medical need). Participants will receive the following study\n      medications by the end of the study:\n\n        -  Ketamine intravenous infusion (IV) AND\n\n        -  Placebo (dummy inactive pill) - this is a tablet that looks like the study drug but has\n           no active ingredient AND\n\n        -  Two doses of TAK-063 at one of three dose levels All participants will be asked to take\n           3 tablets and will receive a ketamine IV on the first day of 3 separate study periods.\n           Participants will then be assessed for brain activity changes and other symptoms. This\n           single-centre trial will be conducted in the United States. The overall time to\n           participate in this study is up to 7 weeks. Participants will make 6 visits to the\n           clinic."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. In the opinion of the investigator, participant is capable of understanding and\n             complying with protocol requirements.\n\n          2. The participant or, when applicable, the participant's legally acceptable\n             representative signs and dates a written, informed consent form and any required\n             privacy authorization prior to the initiation of any study procedures.\n\n          3. Is a healthy adult male.\n\n          4. Speaks English as their first language.\n\n          5. Is aged 18 to 45 years, inclusive, at the time of informed consent and first dose of\n             study drug.\n\n          6. Weighs at least 50 kg and has a body mass index (BMI) between 18 and 32 kg/m^2,\n             inclusive at Screening.\n\n          7. A male participant who is nonsterilized and sexually active with a female partner of\n             childbearing potential agrees to use adequate contraception from signing of informed\n             consent throughout the duration of the study and for 12 weeks after last dose.\n\n          8. Has a normal magnetic resonance imaging (MRI) scan and electroencephalogram (EEG)\n             measurement at Screening.\n\n        Exclusion Criteria:\n\n          1. Has received any investigational compound or ketamine within 30 days prior to Day 1\n             of Period 1.\n\n          2. Has received TAK-063 in a previous clinical study or as a therapeutic agent.\n\n          3. Is an immediate family member, study site employee, or in a dependant relationship\n             with a study site employee who is involved in the conduct of this study (eg, spouse,\n             parent, child, sibling) or may consent under duress.\n\n          4. Has uncontrolled, clinically significant neurologic, cardiovascular, pulmonary,\n             hepatic, renal, metabolic, gastrointestinal, urologic, immunologic, endocrine\n             disease, or psychiatric disorder, or other abnormality (including MRI or EEG), which\n             may impact the ability of the participant to participate or potentially confound the\n             study results.\n\n          5. Has a known hypersensitivity to any component of the formulation of TAK-063 or\n             ketamine.\n\n          6. Has a contraindication for ketamine.\n\n          7. Has a positive result for drugs or alcohol at Screening or Check-in (Day -1 of Period\n             1).\n\n          8. Has a history of drug or alcohol abuse or dependence (as defined by Diagnostic &\n             Statistical Manual of Mental Disorders, fourth Edition [DSM-IV]) within 1 year prior\n             to the screening visit or is unwilling to agree to abstain from alcohol and drugs\n             throughout the study.\n\n          9. Has taken any excluded medication, supplements, or food products listed in the\n             Excluded Medications and Dietary Products.\n\n         10. Has evidence of current cardiovascular, central nervous system (CNS), hepatic,\n             hematopoietic disease, renal dysfunction, metabolic or endocrine dysfunction, serious\n             allergy, asthma hypoxemia, hypertension, seizures, or allergic skin rash. There is\n             any finding in the participant's medical history, physical examination, or safety\n             laboratory tests giving reasonable suspicion of a disease that would contraindicate\n             taking TAK-063 or ketamine or a similar drug in the same class, or that might\n             interfere with the conduct of the study. This includes, but is not limited to, peptic\n             ulcer disease, seizure disorders, and cardiac arrhythmias.\n\n         11. Has current or recent (within 6 months) gastrointestinal disease that would be\n             expected to influence the absorption of drugs (ie, a history of malabsorption,\n             esophageal reflux, peptic ulcer disease, erosive esophagitis frequent [more than once\n             per week] occurrence of heartburn, or any surgical intervention [eg,\n             cholecystectomy]).\n\n         12. Has a history of cancer, except basal cell carcinoma which has been in remission for\n             at least 5 years prior to Day 1 of Period 1.\n\n         13. Has a positive test result for hepatitis B surface antigen (HBsAg), hepatitis C\n             antibody (HCV), or a known history of human immunodeficiency virus infection at\n             Screening.\n\n         14. Has used nicotine-containing products (including but not limited to cigarettes,\n             pipes, cigars, chewing tobacco, nicotine patch or nicotine gum) within 28 days prior\n             to Check-in (Day -1 of Period 1) or cotinine test is positive at Screening or\n             Check-in (Day -1 of Period 1).\n\n         15. Has poor peripheral arterial/venous access or recent wrist trauma.\n\n         16. Has donated or lost 450 mL or more of his or her blood volume (including\n             plasmapheresis), or had a transfusion of any blood product within 3 months prior to\n             Day 1 of Period 1.\n\n         17. Has a Screening and/or Check-in (Day -1 of Period 1) abnormal (clinically\n             significant) electrocardiogram (ECG). Participant has a supine blood pressure outside\n             the ranges of 90 to 140 mm Hg for systolic and 50 to 90 mm Hg for diastolic, if out\n             of range may be repeated once for eligibility determination at the Screening Visit or\n             Check-in (Day -1 of Period 1).\n\n         18. Has a resting heart rate outside the range 50 to 90 beats per minute (bpm), if out of\n             range may be repeated once for eligibility determination at the Screening Visit\n             and/or Check-in (Day -1 of Period 1).\n\n         19. Has a QT interval with Fridericia correction method (QTcF) >430 ms or PR outside the\n             range 120 to 220 ms, if out of range may be repeated once for eligibility\n             determination within a maximum of 5 minutes, at the Screening Visit and/or Check-in\n             (Day -1 of Period 1).\n\n         20. Has abnormal Screening laboratory values that suggest a clinically significant\n             underlying disease or participant with the following lab abnormalities: alanine\n             aminotransferase (ALT) and/or aspartate aminotransferase (AST) >1.5 upper limit of\n             normal (ULN).\n\n         21. Has a history of Axis I/II mental disorders according to DSM-IV Axis I/II such as\n             depression, anxiety disorders, bipolar disorder, attention deficit/hyperactivity\n             disorder (ADHD), autism spectrum disorders, anorexia nervosa, bulimia nervosa, and\n             schizophrenia.\n\n         22. Has a history of head injury or trauma.\n\n         23. Has any condition that would prevent an MRI from accurately or safely being performed\n             (eg, claustrophobia, cardiac pacemaker, metallic implants or clips), as verified per\n             study site's standard MRI assessment questionnaire.\n\n         24. Has a risk of suicide according to the Investigator's clinical judgment (eg, per\n             Columbia-Suicide Severity Rating Scale [C-SSRS]) or has made a suicide attempt in the\n             previous 6 months prior to Screening."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "27", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01892189", 
            "org_study_id": "TAK-063_102", 
            "secondary_id": "U1111-1141-2177"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Sequence 1: Placebo + TAK-063 Dose 1 + TAK-063 Dose 2", 
                    "Sequence 2: TAK-063 Dose 1 + TAK-063 Dose 2 + Placebo", 
                    "Sequence 3: TAK-063 Dose 2 + Placebo + TAK-063 Dose 1", 
                    "Sequence 4: Placebo + TAK-063 Dose 1 + TAK-063 Dose 3", 
                    "Sequence 5: TAK-063 Dose 1 + TAK-063 Dose 3 + Placebo", 
                    "Sequence 6: TAK-063 Dose 3 + Placebo + TAK-063 Dose 1", 
                    "Sequence 7: Placebo + TAK-063 Dose 2 + TAK-063 Dose 3", 
                    "Sequence 8: TAK-063 Dose 2 + TAK-063 Dose 3 + Placebo", 
                    "Sequence 9: TAK-063 Dose 3 + Placebo + TAK-063 Dose 2"
                ], 
                "description": "Ketamine intravenous administration.", 
                "intervention_name": "Ketamine", 
                "intervention_type": "Drug", 
                "other_name": "Ketalar\u2122"
            }, 
            {
                "arm_group_label": [
                    "Sequence 1: Placebo + TAK-063 Dose 1 + TAK-063 Dose 2", 
                    "Sequence 2: TAK-063 Dose 1 + TAK-063 Dose 2 + Placebo", 
                    "Sequence 3: TAK-063 Dose 2 + Placebo + TAK-063 Dose 1", 
                    "Sequence 4: Placebo + TAK-063 Dose 1 + TAK-063 Dose 3", 
                    "Sequence 5: TAK-063 Dose 1 + TAK-063 Dose 3 + Placebo", 
                    "Sequence 6: TAK-063 Dose 3 + Placebo + TAK-063 Dose 1", 
                    "Sequence 7: Placebo + TAK-063 Dose 2 + TAK-063 Dose 3", 
                    "Sequence 8: TAK-063 Dose 2 + TAK-063 Dose 3 + Placebo", 
                    "Sequence 9: TAK-063 Dose 3 + Placebo + TAK-063 Dose 2"
                ], 
                "description": "TAK-063 tablets", 
                "intervention_name": "TAK-063", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sequence 1: Placebo + TAK-063 Dose 1 + TAK-063 Dose 2", 
                    "Sequence 2: TAK-063 Dose 1 + TAK-063 Dose 2 + Placebo", 
                    "Sequence 3: TAK-063 Dose 2 + Placebo + TAK-063 Dose 1", 
                    "Sequence 4: Placebo + TAK-063 Dose 1 + TAK-063 Dose 3", 
                    "Sequence 5: TAK-063 Dose 1 + TAK-063 Dose 3 + Placebo", 
                    "Sequence 6: TAK-063 Dose 3 + Placebo + TAK-063 Dose 1", 
                    "Sequence 7: Placebo + TAK-063 Dose 2 + TAK-063 Dose 3", 
                    "Sequence 8: TAK-063 Dose 2 + TAK-063 Dose 3 + Placebo", 
                    "Sequence 9: TAK-063 Dose 3 + Placebo + TAK-063 Dose 2"
                ], 
                "description": "TAK-063 placebo-matching tablets", 
                "intervention_name": "TAK-063 Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ketamine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Drug therapy", 
        "lastchanged_date": "November 18, 2013", 
        "location": {
            "contact": {
                "email": "Deborah.Yurgelun-Todd@hsc.utah.edu", 
                "last_name": "801-587-1471 Yurgelun-Todd", 
                "phone": "801-587-1471"
            }, 
            "facility": {
                "address": {
                    "city": "Salt Lake City", 
                    "country": "United States", 
                    "state": "Utah", 
                    "zip": "84108"
                }, 
                "name": "The Brain Institute, University of Utah"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "9", 
        "official_title": "A Randomized, Investigator and Subject-Blind, Placebo-Controlled, Single-Dose, 3-Period, Incomplete Block Cross-Over Study to Evaluate the Effects of Single Oral Administration of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults", 
        "overall_contact": {
            "email": "medicalinformation@tpna.com", 
            "last_name": "Takeda Study Registration Call Center", 
            "phone": "800-778-2860"
        }, 
        "overall_official": {
            "affiliation": "Takeda Development Center Americas, Inc.", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Brain activity will be measured by functional magnetic resonance imaging (fMRI) blood-oxygen-level-dependent (BOLD). Areas of interest in brain activity are defined as the Anterior Cingulate Cortex, Posterior Cingulate Cortex, Striatum, Amygdala, Substantia Nigra, Thalamus, and Ventrolateral Prefrontal Cortex.", 
            "measure": "Ketamine-induced brain activity in regions of interest during Resting State", 
            "safety_issue": "No", 
            "time_frame": "4 hours post-dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01892189"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.", 
                "measure": "Cmax: Maximum Observed Plasma Concentration Pharmacokinetic Parameter for TAK-063 and TAK-063 metabolite M-I", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "description": "Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax.", 
                "measure": "Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) Pharmacokinetic Parameter for TAK-063 and TAK-063 metabolite M-I", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "description": "(AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]).", 
                "measure": "AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration Pharmacokinetic Parameter for TAK-063 and TAK-063 metabolite M-I", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "description": "A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug (AE start date \u2265 first dose date) and within 30 days after receiving the last dose of study drug (AE start date - last dose date \u226430).", 
                "measure": "Percentage of participants who experience at least one treatment emergent adverse event (TEAE)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 days after last dose of TAK-063"
            }, 
            {
                "description": "The percentage of participants with any markedly abnormal standard safety laboratory values after the dose of TAK-063.", 
                "measure": "Percentage of participants with markedly abnormal safety laboratory tests", 
                "safety_issue": "Yes", 
                "time_frame": "14 days after last dose of TAK-063."
            }, 
            {
                "description": "The percentage of participants who meet markedly abnormal criteria for vital signs after the dose of TAK-063.", 
                "measure": "Percentage of participants with markedly abnormal vital sign measurements", 
                "safety_issue": "Yes", 
                "time_frame": "14 days after last dose of TAK-063."
            }, 
            {
                "description": "The percentage of participants who meet markedly abnormal criteria after the dose of TAK-063.", 
                "measure": "Percentage of participants with markedly abnormal criteria for safety electrocardiogram (ECG) parameters", 
                "safety_issue": "Yes", 
                "time_frame": "14 days after last dose of TAK-063."
            }
        ], 
        "source": "Takeda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}